13.17
price down icon0.53%   -0.07
after-market Handel nachbörslich: 13.17
loading

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

pulisher
Oct 14, 2025

What sentiment indicators say about NovoCure Limited stockTrade Risk Assessment & Daily Volume Surge Signals - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Should you wait for a breakout in NovoCure LimitedPortfolio Performance Summary & Stepwise Trade Execution Plans - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Is NovoCure Limited stock ready for a breakout2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone - simplywall.st

Oct 12, 2025
pulisher
Oct 10, 2025

Using data tools to time your NovoCure Limited exitJuly 2025 Trends & Target Return Focused Stock Picks - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

NovoCure's (NVCR) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR) - Sahm

Oct 10, 2025
pulisher
Oct 10, 2025

Should I buy NovoCure Limited (038) stock before earnings seasonJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Why NovoCure Limited (038) stock remains top ratedEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 09, 2025
pulisher
Oct 08, 2025

NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World

Oct 08, 2025
pulisher
Oct 07, 2025

NovoCure Limited (NVCR) Stock Analysis: A Closer Look at an 87.5% Potential Upside in the Medical Device Sector - DirectorsTalk Interviews

Oct 07, 2025
pulisher
Oct 07, 2025

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Analysts - Defense World

Oct 07, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 04:02:03 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Analyzing NovoCure Limited with multi timeframe chartsQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled - simplywall.st

Oct 04, 2025
pulisher
Oct 03, 2025

Volume spikes in NovoCure Limited stock – what they mean2025 Support & Resistance & Capital Protection Trading Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will NovoCure Limited (038) stock keep high P E multiplesRecession Risk & Safe Entry Trade Signal Reports - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases - simplywall.st

Oct 03, 2025
pulisher
Oct 02, 2025

How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Medical Technology Firm Novocure Schedules Q3 2025 Financial Results with Investor Conference Call - Stock Titan

Oct 01, 2025
pulisher
Oct 01, 2025

Novocure to Report Third Quarter 2025 Financial Results - The Globe and Mail

Oct 01, 2025
pulisher
Oct 01, 2025

Why NovoCure Limited is moving todayQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com Nigeria

Sep 30, 2025
pulisher
Sep 30, 2025

NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Pattern recognition hints at NovoCure Limited upsideTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Novocure (NVCR) Announces Positive Phase 3 METIS Trial Results - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Novocure’s cancer therapy delays brain metastases progression By Investing.com - Investing.com Australia

Sep 29, 2025
pulisher
Sep 29, 2025

Novocure’s cancer therapy delays brain metastases progression - Investing.com India

Sep 29, 2025
pulisher
Sep 29, 2025

15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan

Sep 29, 2025
pulisher
Sep 29, 2025

Live market analysis of NovoCure LimitedJuly 2025 Selloffs & Safe Entry Point Identification - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Why NovoCure Limited stock is rated strong buyJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Washington Capital Management Inc. Invests $374,000 in NovoCure Limited $NVCR - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

How NovoCure Limited stock benefits from strong dollarJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Regression analysis insights on NovoCure Limited performancePortfolio Risk Report & Fast Gain Swing Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-28 23:33:37 - newser.com

Sep 29, 2025
pulisher
Sep 27, 2025

NovoCure Limited stock outlook for YEARJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Is NovoCure Limited (038) stock a buy on weaknessJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com

Sep 26, 2025
pulisher
Sep 24, 2025

42,600 Shares in NovoCure Limited $NVCR Purchased by Strs Ohio - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer - simplywall.st

Sep 23, 2025
pulisher
Sep 21, 2025

NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy - simplywall.st

Sep 21, 2025
$318.30
price up icon 1.19%
medical_devices STE
$237.81
price up icon 0.99%
$66.21
price up icon 1.55%
medical_devices PHG
$27.15
price down icon 1.27%
$72.34
price up icon 0.70%
medical_devices EW
$73.36
price up icon 0.56%
Kapitalisierung:     |  Volumen (24h):